Solid Tumor with Infection
Conditions
Interventions
Experimental group 1:Tezhixing + Colimycin
Control group 1:Tezhixing
Experimental group 2:Tezhixing + Meiping + Colimycin
Control group 2:Tezhixing + Meiping
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients with solid tumor diagnosed by histopathology or cytology or patients with tumor history; 2.In the case of solid tumor with infection, the pathogenic microorganism is determined as CRO; 3.CRO: sputum culture of carbapenem resistant Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii; 4.Age greater than 18 years old (including boundary value), male and female are not limited; 5.The subject or legal representative has signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients known to be allergic to the study drug or active ingredient; 2.Patients with bloodstream infection; 3.Patients with liver dysfunction (ALT and/or AST 2.5 times the upper limit of normal, and/or total bilirubin 1.5 times the upper limit of normal, or Child Pugh grade C); 4.Patients with severe renal function injury (creatinine clearance < 30ml / min); 5.Clinically serious gastrointestinal dysfunction may affect the intake, transport or absorption of the study drug, such as uncontrollable nausea or vomiting, history of large-scale gastrointestinal resection, incurable recurrent diarrhea, Crohn's disease and ulcerative colitis; 6.Combined use of warfarin, anticonvulsant drugs, statins, cisapride, immunosuppressive drugs, digoxin and ergot drugs; 7.Patients use macrolides, aminoglycosides, tetracyclines, linezolid and other drugs to inhibit the protein synthesis of pathogenic microorganisms; 8.Patients have participated in other clinical trials within 4 weeks before screening or are participating in other clinical trials; 9.Pregnant women, lactating women and subjects (including male subjects) have pregnancy plans (including sperm donation and egg donation plans) or are unable to take effective contraceptive measures in the next 6 months; 10.Other circumstances that the investigator considers unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Leukocyte count;C-reaction protein;Procalcitonin; | — |
Countries
China
Contacts
Public ContactHuang Weifeng
Shanghai Sixth People's Hospital
Outcome results
None listed